Stent: Supply chain
Main companies
The largest makers and their shares
| Company | Country | Measure | Year | Source |
|---|---|---|---|---|
| Abbott Vascular, Boston Scientific and Medtronic | – | Named as the foreign stent companies in India [10]; multinationals together held around 60% of India's market in 2016 [9]. No world shares found | 2016 | [10][9] |
| Meril Life Sciences | India | Produces more than 60,000 stents every year (MD+DI, 2013). No market share found | 2013 | [15] |
| Johnson & Johnson (Cordis) | United States of America | Launched the Palmaz-Schatz stent in the United States in 1994 [7]; its Cypher (with Cordis) was the first drug-eluting stent approved by the FDA, in 2003 [8]. No share found | 2003 | [7][8] |
| Cook Medical | United States of America | Maker of the Gianturco-Roubin Flex-Stent, approved by the FDA in 1993 and already marketed in Australia, Korea and Singapore. No share found | 1993 | [6][22] |
| Medtronic | – | Company segment, not stent output: Coronary & Peripheral Vascular had revenue of USD 2,535 million in fiscal 2025 (table value); the segment also sells guide catheters and balloons | 2025 | [21] |
as of 2026-11-13
Supply chains of the main makers
For the top three to five producing countries and India: share, where inputs and components come from, main makers and how variants differ
| Country | Inputs from | Makers | How variants differ | Year | Source |
|---|---|---|---|---|---|
| India | No source opened says where India's stent materials come from | Indian makers such as Meril Life Sciences [15]; multinationals Abbott Vascular, Boston Scientific and Medtronic [10] | Indigenous stents held under 40% of the market and multinationals around 60% in 2016; over 60% of drug-eluting stents were made by multinationals [9] | 2016 | [9][10][15] |
as of 2026-11-13
Industries that make it
The industries and kinds of firm that make it
Made by- Medical-device companies (OEMs) World Device firms such as Abbott Vascular, Boston Scientific, Medtronic and Johnson & Johnson (Cordis) make stents [10][7].
as of 2026-11-13
Rules and standards
Labels, efficiency and emission standards, producer responsibility, bans and tariffs
| Rule | Place | Year | What it does | Source |
|---|---|---|---|---|
| NPPA notification S.O. 412(E): ceiling prices of coronary stents | India | 2017 | Capped bare metal stents at INR 7,260 and drug-eluting stents at INR 29,600; the drug-eluting cap covers bioresorbable scaffolds too | [11][9][23][13] |
| NPPA notification S.O. 639(E): revised ceiling prices | India | 2018 | Revised the caps to INR 27,890 for drug-eluting and INR 7,660 for bare metal stents, from INR 30,180 and INR 7,400 [11]; hospitals that bill patients directly must keep to the ceiling and list the stent's cost, type, brand and maker on the bill [25] | [11][25] |
| Coronary stents added to the National List of Essential Medicines, 2015 and to Schedule I of the Drugs (Prices Control) Order, 2013 | India | 2016 | Added to the list on 19 July 2016 and to Schedule I on 21 December 2016, which brings stents under NPPA ceiling prices | [23][25] |
| CDSCO classification of devices under the Medical Devices Rules, 2017 (notice of 1 November 2017) | India | 2017 | Lists the coronary stent, the bioresorbable vascular scaffold system and the drug-eluting stent in risk class D | [14] |
| Premarket approval of drug-eluting stents, for example PMA P070015 for the XIENCE V | United States of America | 2008 | The FDA publishes a summary of safety and effectiveness for each approved drug-eluting stent | [3] |
| Regulation (EU) 2017/745, Annex VIII, Rule 8 | European Union | 2017 | Implants in direct contact with the heart or central circulatory system, which the Annex defines to include the coronary arteries, are class III | [19] |
as of 2026-11-13
India
India's output, trade, makers and rules in a short paragraph
One estimate puts stents used in India at 594,000 in 2016, with multinationals holding around 60% of the market [9]. NPPA fixed ceiling prices on 13 February 2017 and revised them on 12 February 2018 [11]; in February 2026 the ceilings were INR 10,692.69 for bare metal and INR 38,933.14 for drug-eluting stents [25]. Trade margins before the cap were up to 654% [12]. CDSCO lists coronary stents in risk class D [14]. No source opened gives output or imports.
as of 2026-11-13
Trade
World exports, the top exporters and importers and India, from UN Comtrade by HS code (worked out by the site)
| Flow | Value | Unit | Volume | Unit | Year | Source |
|---|---|---|---|---|---|---|
| World exports | 18.4 | USD billion | 30.2 | thousand tonnes | 2024 | UN Comtrade, HS 9021.90 |
| Average export value (calculated) | 609.28 | USD per kg | – | – | 2024 | UN Comtrade, HS 9021.90 |
| Exporter: United States (15.5% of world exports) | 2.85 | USD billion | 2.6 | thousand tonnes | 2024 | UN Comtrade, HS 9021.90 |
| Exporter: Netherlands (15.2% of world exports) | 2.79 | USD billion | – | – | 2024 | UN Comtrade, HS 9021.90 |
| Exporter: Ireland (13.2% of world exports) | 2.43 | USD billion | 0.7 | thousand tonnes | 2024 | UN Comtrade, HS 9021.90 |
| Exporter: Germany (11.0% of world exports) | 2.02 | USD billion | 1.7 | thousand tonnes | 2024 | UN Comtrade, HS 9021.90 |
| Exporter: Malaysia (5.7% of world exports) | 1.04 | USD billion | – | – | 2024 | UN Comtrade, HS 9021.90 |
| India exports (rank 24, 0.3% of world) | 0.06 | USD billion | 0.3 | thousand tonnes | 2024 | UN Comtrade, HS 9021.90 |
| India imports (rank 17, 1.6% of world) | 0.27 | USD billion | 0.5 | thousand tonnes | 2024 | UN Comtrade, HS 9021.90 |
| Importer: United States (11.7% of world imports) | 1.97 | USD billion | 1.9 | thousand tonnes | 2024 | UN Comtrade, HS 9021.90 |
| Importer: Netherlands (11.3% of world imports) | 1.91 | USD billion | 3.5 | thousand tonnes | 2024 | UN Comtrade, HS 9021.90 |
| Importer: Germany (9.8% of world imports) | 1.66 | USD billion | 3.3 | thousand tonnes | 2024 | UN Comtrade, HS 9021.90 |
Worked out from data
Sources
- Summary of Safety and Effectiveness Data, XIENCE V Everolimus Eluting Coronary Stent System (PMA P070015) US Food and Drug Administration (applicant Abbott Vascular, Cardiac Therapies), 2008, FDA notice of approval 2 July 2008; device description
- Inception of the coronary stent: a story of successful collaboration between innovative scientists and the biotechnology industry REC: Interventional Cardiology 6(4):321-331 (Macaya-Ten, Gonzalo, Escaned, Macaya), 2024
- The Surprising History Behind an Extremely Common Cardiovascular Medical Device MD+DI, no byline or date shown on the page
- Stents at 25 years: A revolution in revascularization Healio (Cardiology Today, Brian Ellis), 2011, dated April 01, 2011
- The new pricing policy for coronary stents in India: a boon or a bane? EuroIntervention (Upendra Kaul), 2017, EuroIntervention 2017;13(3), published 20 June 2017, DOI 10.4244/EIJV13I3A40
- Price-cap is after all just a new price: The case of cardiac stents in India Observer Research Foundation (Ramesh Bhat and Denny John), 2017, Issue Brief, published 27 April 2017; Table 1, estimates compiled by the authors from National Intervention Council presentations and reports
- Lok Sabha Unstarred Question No. 2781, Guidelines by NPPA, answered 13 March 2018 Lok Sabha, Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals), 2018
- Lok Sabha Unstarred Question No. 681, Trade Margins on Medical Devices, answered 19 December 2017 Lok Sabha, Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals), 2017
- NPPA puts price cap on cardiac stents; says hospitals overcharge Down To Earth (Kundan Pandey), 2017, published 14 February 2017
- Classification of medical devices and in vitro diagnostic medical devices under the provisions of the Medical Devices Rules, 2017 - Reg. Central Drugs Standard Control Organisation (Drugs Controller General of India), 2017, File No. 29/Misc.13/2017-DC(292), dated 1 November 2017; list entries 9, 10 and 205
- Indian Stent Makers Give Boston Sci, Medtronic, and Abbott a Run for Their Money MD+DI, 2013, dated 14 January 2013; no author named
- Regulation (EU) 2017/745 of the European Parliament and of the Council, Annex VIII (classification rules, original version) legislation.gov.uk (retained EU text), 2017
- Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase Medtronic, 2025, dated 21 May 2025; Worldwide Revenue table, (in millions)
- Cook's Gianturco-Roubin Flex-Stent is first coronary stent approved by FDA (title from the page address; the page text shows no headline) The Gray Sheet, on Medtech Insight (Informa), no date shown; the text gives the FDA panel of May 1992 and approval on 'May 28', which REC (2024) places in 1993
- Mission to provide Affordable, Quality Healthcare for All: Coronary Stent Prices capped, to bring down cost by about 380% Press Information Bureau, Government of India (Ministry of Chemicals and Fertilizers), 2017, posted 14 February 2017
- Increase in the Price of Cardiac Stents Press Information Bureau, Government of India (Ministry of Chemicals and Fertilizers), 2026, dated 13 February 2026